In Brief: Glaxo
This article was originally published in The Tan Sheet
Executive Summary
Glaxo: Supplementary NDA for use of Flonase nasal spray in children ages 4-11 for treatment of seasonal and perennial allergic rhinitis filed Oct. 31, the company announces Dec. 5. Flonase (fluticasone propionate), an Rx product that is a potential candidate for OTC switch, is a once-a-day spray indicated for treatment of seasonal and perennial nasal allergies in patients 12 and older, the company says, adding that the product is not yet indicated for treatment of allergic rhinitis...